Steve’s principle research focus is on the discovery and development of novel anti-infective drugs targeting pathogens of significant public health concern including: malaria, TB, neglected tropical diseases, antimicrobial resistance organisms, and emerging threats such as SARs-Cov2. His research expertise extends from early drug discovery, through formal regulatory pre-clinical and clinical evaluation and through to field deployment of new therapeutic interventions. To support these efforts there is a focus on understanding fundamental pathogen-specific biological processes related to mechanisms of drug action and drug resistance with a view to identifying unique targets/strategies that can be integrated into the drug discovery cycle. Current research programmes include, initiatives focussed on the discovery and development of drugs for malaria, TB and filariasis, studies into the molecular and biochemical basis of drug resistance in human pathogens, molecular and biochemical drug target identification and validation, development of pharmacokinetic / pharmacodynamic clinical and preclinical models to aid effective chemotherapy, clinical pharmacology of anti-infective agents, systems pharmacology of anti-infective agents using high content imaging, metabolomics. proteomics, transcriptomics and mathematical modelling.